Monoclonal Antibodies
Monoclonal Antibodies Companies (10)
Monoclonal Antibodies News
-
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Amgen launches first biosimilar to Humira® in US
AMJEVITA, a biosimilar to Abbvie, Inc.’s Humira®, has been launched in the US by Amgen for the treatment of several inflammatory diseases, with the goal of both providing treatments to patients and reducing healthcare costs. -
News Eli Lilly's Alzheimer's drug falls short for accelerated approval from the FDA
Eli Lilly's Alzheimer's drug donanemab is rejected for accelerated approval by the US FDA, but the clinical trial data still shows promise for coming up for standard approval later in the year. -
News Streamlined Development for Efficient Production of Bispecific Molecules: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overv...
Monoclonal Antibodies Products (10)
-
Product SUREmAb™
Built on the SUREtechnology Platform, SUREmAb optimizes monoclonal antibody (mAb) development and manufacturing processes, fast-tracking the path to clinic and market. • Fast-tracked for efficiency and speed, taking you from DNA transfection to GMP drug substance in 11 months • Comprehensive mAb develop... -
Product Biologic drug substance CDMO services
From pre-clinical development to commercial supply, Patheon by Thermo Fisher Scientific is an industry leader in the development and manufacture of mammalian cell culture drug substances. Patheon offers biotech and pharmaceutical companies the ability to pursue opportunities around the globe with a fully i... -
Product MabionCD20
This is our most advanced in-house project. A MabThera/Rituxan (rituximab) biosimilar drug, whose efficacy and safety were clinically confirmed. It is the first such advanced drug developed in Poland. We are currently at the final stage of works aimed at marketing the drug in Europe and the United States. -
Product Nimotuzumab
Nimotuzumab binds with intermediate affinity and high specificity to the extracellular domain of EGFR and blocks the binding of the EGF to its receptor and inhibits tumor cell growth. The molecule induces cell lysis through ADCC mechanism. Nimotuzumab provides vaccinal effect that induce memory T-cell ... -
Product Bevacizumab
Bevacizumab acts by selectively binding circulating VEGF, thereby inhibiting the binding of VEGF to its cell surface receptors. This inhibition leads to a reduction in microvascular growth of tumor blood vessels that limits the blood supply to tumor tissues.The indication is for Colorectal Cancer... -
Product Novel Hyaluronidase (ALT-B4) Hybrozyme™
A novel and proprietary hyaluronidase to enable subcutaneous administration of IV biologics. Currently partnered with 4 global pharmaceutical companies including two Top 10 global pharmaceutical companies. ALT-B4 has enhanced thermal stability and protein stability leading to longer shelf-life, has higher ... -
Product Serum-Free and chemically defined Medium/Media
Our Media are designed for small- and large-scale biomanufacturing and feature full and easy scalability.
-
Product Fermenters
Fermentation is mostly extracellular activity and is brought with the help of enzymes released by the microorganisms. The Fermenter is designed to meet all process requirement for micro-organism to achieve maximum growth and productivity. Features:
• Fully automated or semi-automated models
• 21... -
Product 3M™ Zeta Plus™
For optimal clarification of biopharmaceutical manufacturing fluids, 3M’s extensive line of depth filters is versatile and adaptable for many processes. Our pharmaceutical-grade filters have high contaminant-holding capacity and provide economical filtration with reliable particle reduction. -
Product Prolgolimab
Prolgolimab is the original fully human anti-PD1 monoclonal antibody for the treatment of advanced melanoma, advanced NSCLC and metastatic cervical cancer. Pending approval in Russia for melanoma in 2019. For marketing authorization in EU BIOCAD is starting Phase III clinical trials.
Upcoming Events
-
CPHI & PMEC China 2024
Shanghai New International Expo Center
19 - 21 June 2024 -
CPHI South East Asia 2024
Queen Sirikit National Convention Center, Bangkok, Thailand
10 Jul 2024 - 12 Jul 2024 -
CPHI Korea 2024
COEX, Seoul, Korea
27 - 29 August 2024
Pharmaceutical Industry Webinars
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance